Press release
ADCs CMO & CDMO Market Outlook 2025-2031: Key Drivers, Emerging Technologies, and Strategic Collaborations Unveiled
Antibody-drug Conjugates (ADCs) CMO and CDMO Market SizeThe global market for Antibody-drug Conjugates (ADCs) CMO and CDMO was valued at US$ 3863 million in the year 2024 and is projected to reach a revised size of US$ 12840 million by 2031, growing at a CAGR of 19.0% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-26P18765/Global_Antibody_drug_Conjugates_ADCs_CMO_and_CDMO_Market_Research_Report_2025
North American market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Inquire for Discount: https://reports.valuates.com/request/discount/QYRE-Auto-26P18765/global-antibody-drug-conjugates-adcs-cmo-and-cdmo
The major global companies of Antibody-drug Conjugates (ADCs) CMO and CDMO include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugates (ADCs) CMO and CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugates (ADCs) CMO and CDMO.
The Antibody-drug Conjugates (ADCs) CMO and CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-drug Conjugates (ADCs) CMO and CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
By Type
• Cleavable linkers
• Non-cleavable linkers
By Application
• Solid Tumors
• Hematological Malignanciesncies
Key Companies
Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology, TOT Biopharm, Huadong Medicine, Innovent Biologics, Shanghai Henlius Biotech
View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-26P18765/global-antibody-drug-conjugates-adcs-cmo-and-cdmo
Please reach us at sales@valuates.com
Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066
Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ADCs CMO & CDMO Market Outlook 2025-2031: Key Drivers, Emerging Technologies, and Strategic Collaborations Unveiled here
News-ID: 4043245 • Views: …
More Releases from Valuates Reports
Conductive Fabric Market Set to Surge - Key Insights You Must Know
Conductive Fabric Market Size
In 2024, the global market size of Conductive Fabric was estimated to be worth US$ 3398 million and is forecast to reach approximately US$ 4493 million by 2031 with a CAGR of 4.1% during the forecast period 2025-2031.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-9R12349/Global_Conductive_Fabric_Market_Size_Manufacturers_Supply_Chain_Sales_Channel_and_Clients_2022_2028
Global key players of Conductive Fabric include Laird Technology Group, Shenzhen Feirongda Technology Co., Ltd., Parker Chomerics, etc. The top three players hold a share over 52%.…
Nonwoven Needle Felt Market Set to Surge - Key Insights You Must Know
Nonwoven Needle Felt Market
Nonwoven Needle Felt is a type of industrial textile usually made from synthetic or natural fibers. Its production process is to mix and pre-treat fiber materials, and then use a special needle punching process to interweave the fibers together to form a felt-like structure. Nonwoven Needle Felt is widely used in filter materials, industrial fabrics, sound insulation materials, padding, carpet base fabrics, automotive interiors and other industrial…
Textile Auxiliaries Market Set to Surge - Key Insights You Must Know
Textile Auxiliaries Market Size
The global market for Textile Auxiliaries was estimated to be worth US$ 7086.7 million in 2023 and is forecast to a readjusted size of US$ 8949.6 million by 2030 with a CAGR of 2.9% during the forecast period 2024-2030
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-30Y7504/Global_Textile_Auxiliaries_Market_Insights_and_Forecast_to_2028
Major Trends
Expanding apparel production, rising technical textile applications, and stricter wastewater norms fuel the textile auxiliaries market. Pre treatment, dyeing, and finishing chemicals enhance fabric performance…
Digital Textile Printing Inks Market Set to Surge - Key Insights You Must Know
Digital Textile Printing Inks Market Size
The global Digital Textile Printing Inks market is projected to grow from US$ 835.3 million in 2024 to US$ 1605.2 million by 2030, at a Compound Annual Growth Rate (CAGR) of 11.5% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-39U9615/Global_Digital_Textile_Printing_Inks_Market_Insights_Forecast_to_2028
Digital textile printing inks are formulated for use in inkjet printers designed for textile applications. These inks provide vibrant colors, excellent colorfastness, and precise printing on fabrics.
Customization…
More Releases for Conjugates
Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
DLL3 Antibody-Drug Conjugates: Mechanisms and Efficacy
Antibody-drug conjugates (ADCs) represent a revolutionary approach in cancer treatment, combining the targeting capabilities of antibodies with the cytotoxic power of chemotherapy. DLL3 (Delta-Like Ligand 3) has emerged as a promising target for ADCs, particularly in the treatment of small cell lung cancer (SCLC) and other neuroendocrine tumors. This article explores the mechanisms and efficacy of DLL3 ADCs, shedding light on their potential in modern oncology.
Download Report:
https://www.kuickresearch.com/report-dll3-targeted-therapies-dll3-cancer-therapies-dll3-protien-dll3-cancer-drugs-delta-like-ligand-3-dll3-gene-dll3-expression-dll3-amgen-dll3-inhibitor
DLL3 is a…
Radionuclide Drug Conjugates (RDC) Market Minimizing Side Effects, Maximizing Im …
Radionuclide Drug Conjugates (RDCs) Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook…
Oncology Antibody Drug Conjugates Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Oncology Antibody Drug Conjugates Market is projected to grow from USD 9.87 billion in 2022 to USD 22.48 billion at a CAGR value of 12.4% from 2022 to 2027.
Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Daiichi Sankyo, AstraZeneca, Sanofi, AbbVie, Merck & Co., Byondis, RemeGen, ImmunoGen, Seagen, Rakuten Medical,…
Global Antibody Drug Conjugates Market Insights, Forecast
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement…